Business Description
Eiger BioPharmaceuticals Inc
NAICS : 325414
SIC : 2836
ISIN : US28249U1051
Description
Eiger BioPharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.96 | |||||
| Equity-to-Asset | -0.03 | |||||
| Debt-to-Equity | -25.52 | |||||
| Debt-to-EBITDA | -0.51 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -16.15 | |||||
| Beneish M-Score | -3.85 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 8.9 | |||||
| 3-Year EPS without NRI Growth Rate | 9 | |||||
| 3-Year FCF Growth Rate | 10.7 | |||||
| 3-Year Book Growth Rate | -18.3 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 28.13 | |||||
| 9-Day RSI | 40.22 | |||||
| 14-Day RSI | 44.3 | |||||
| 6-1 Month Momentum % | -61.94 | |||||
| 12-1 Month Momentum % | -67.69 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.31 | |||||
| Quick Ratio | 3.24 | |||||
| Cash Ratio | 2.39 | |||||
| Days Inventory | 3598.52 | |||||
| Days Sales Outstanding | 65.37 | |||||
| Days Payable | 11204.41 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -21.6 | |||||
| Shareholder Yield % | -33.53 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 98.17 | |||||
| Operating Margin % | -570.32 | |||||
| Net Margin % | -590.8 | |||||
| FCF Margin % | -566.44 | |||||
| ROE % | -237.33 | |||||
| ROA % | -88.21 | |||||
| ROIC % | -1009.97 | |||||
| ROC (Joel Greenblatt) % | -7117.89 | |||||
| ROCE % | -106.35 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.91 | |||||
| EV-to-EBIT | -0.18 | |||||
| EV-to-EBITDA | -0.18 | |||||
| EV-to-Revenue | 1.01 | |||||
| EV-to-FCF | -0.18 | |||||
| Earnings Yield (Greenblatt) % | -555.56 | |||||
| FCF Yield % | -622.23 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:EIGR
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Eiger BioPharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 14.666 | ||
| EPS (TTM) ($) | -1.97 | ||
| Beta | 2.27 | ||
| Volatility % | 143.01 | ||
| 14-Day RSI | 44.3 | ||
| 14-Day ATR ($) | 0.052241 | ||
| 20-Day SMA ($) | 0.33554 | ||
| 12-1 Month Momentum % | -67.69 | ||
| 52-Week Range ($) | 0.21 - 2.98 | ||
| Shares Outstanding (Mil) | 44.38 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Eiger BioPharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Eiger BioPharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Eiger BioPharmaceuticals Inc Frequently Asked Questions
What is Eiger BioPharmaceuticals Inc(EIGR)'s stock price today?
The current price of EIGR is $0.30. The 52 week high of EIGR is $2.98 and 52 week low is $0.21.
When is next earnings date of Eiger BioPharmaceuticals Inc(EIGR)?
The next earnings date of Eiger BioPharmaceuticals Inc(EIGR) is 2024-03-15 Est..
Does Eiger BioPharmaceuticals Inc(EIGR) pay dividends? If so, how much?
Eiger BioPharmaceuticals Inc(EIGR) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers